Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 15/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034467 | 0.89 | PTK2 (0.44) | KITFLT3PTK2LRRK2 | |
| SCHEMBL2034472 | 0.86 | PTK2 (0.44) | KITFLT3PTK2AURKALRRK2 | |
| SCHEMBL2637079 | 0.86 | KIT (0.43) | KITFLT3PTK2AURKALRRK2 | |
| SCHEMBL15227404 | 0.86 | KIT (0.43) | KITFLT3PTK2AURKALRRK2 | |
| SCHEMBL2032989 | 0.82 | LRRK2 (0.44) | KITFLT3PTK2AURKALRRK2 | |
| SCHEMBL2637440 | 0.80 | LRRK2 (0.43) | KITFLT3PTK2AURKALRRK2 | |
| SCHEMBL2636859 | 0.80 | LRRK2 (0.49) | PTK2LRRK2 | |
| SCHEMBL2637631 | 0.80 | EGFR (0.44) | KITFLT3PTK2LRRK2FGFR1 | |
| SCHEMBL2637046 | 0.80 | CHEK1 (0.46) | KITFLT3PTK2LRRK2FGFR1 | |
| SCHEMBL2637349 | 0.80 | LRRK2 (0.45) | KITFLT3PTK2AURKALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096624-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2438056-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010141406-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | KIT 1208/4885FLT3 27/4885PTK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.